

8 December 2025

Corporate Update

Argent BioPharma Limited (ASX: RGT) (**Company**) advises that it has terminated the employment agreement of Mr Igor Bluvstein, who served as the Company's Chief Financial Officer. Mr Bluvstein has also been removed from all positions held within the Company's subsidiaries, effective immediately.

As part of its ongoing operational improvement program, the Company is restructuring its finance and reporting functions to ensure a more efficient, scalable, and transparent operational framework. Accordingly, Argent BioPharma will transition all financial management activities from the internal team in Slovenia to a dedicated external accounting and finance provider in Australia.

This transition forms a key element of the Company's move to a leaner and more effective organisational structure, designed to support its commercial, clinical, and regulatory objectives. The centralisation of financial oversight in Australia will enhance governance, improve reporting quality, and better align the Company's operations with the requirements of its planned U.S. listing.

Argent BioPharma remains strongly focused on progressing its R&D programs, advancing clinical development, and delivering on its upcoming regulatory and commercial milestones.

-ENDS-

Authorised for release by the managing director, for further information, please contact:

Argent BioPharma

Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma

Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company developing nano-engineered medicines that restore balance between the nervous and immune systems. Its lead candidates, CannEpil® and CimetrA®, target drug-resistant epilepsy and cytokine-driven inflammatory and autoimmune disorders, respectively. The Company's proprietary delivery platforms are designed to improve penetration across the blood-brain and alveolar-capillary barriers, enabling differentiated efficacy and supporting composition-of-matter protection. With EU-GMP manufacturing, advancing late-stage clinical programs, and a unified Neuro-Immune Modulatory platform, Argent BioPharma is building a high-impact pipeline with a clear focus on urgent unmet needs in CNS and systemic inflammation.

Follow us through our social media channels:

LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma